MedTrace Logo

A Study of Teduglutide (Revestive®) in Children, Teenagers and Adults With Short Bowel Disease

NCT04877431 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 45

Last updated 2023-07-19

No results posted yet for this study

Summary

The main aims of the study are to assess the safety profile of Teduglutide (Revestive®) in people with Short Bowel Disease as well as how well people respond to the treatment with Teduglutide (Revestive®).

This study is about collecting data only; participants receive Teduglutide (Revestive®) by their doctors according to the clinical practice but not as part of this study. Only standard care information available in the participant's medical records will be reviewed and collected for this study.

Participants do not need to visit their doctor in addition to their normal visits.

Conditions

  • Short Bowel Syndrome

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-05
Primary Completion
2023-06-05
Completion
2023-06-05

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04877431 on ClinicalTrials.gov